Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The utility of a telemedicine platform to monitor adherence and adverse effects of tyrosine kinase inhibitors.

Copeland AC, Foster MC, Muluneh B, Xenakis JG, Ivanova A, Frankfurt O, Clayton M, Black A, Rapchak B, Wehbie RS.

Leuk Lymphoma. 2019 Feb 18:1-3. doi: 10.1080/10428194.2018.1551540. [Epub ahead of print] No abstract available.

PMID:
30773105
2.

Factors Influencing Adherence in Cancer Patients Taking Oral Tyrosine Kinase Inhibitors: A Qualitative Study.

Verbrugghe M, Duprez V, Beeckman D, Grypdonck M, Quaghebeur M, Verschueren C, Verhaeghe S, Van Hecke A.

Cancer Nurs. 2016 Mar-Apr;39(2):153-62. doi: 10.1097/NCC.0000000000000250.

PMID:
25815430
3.

Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.

Anderson KR, Chambers CR, Lam N, Yau PS, Cusano F, Savoie ML, Sheikh N.

J Oncol Pharm Pract. 2015 Feb;21(1):19-25. doi: 10.1177/1078155213520261. Epub 2014 Feb 6.

PMID:
24503243
4.

Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective?

Treskes RW, Van der Velde ET, Schoones JW, Schalij MJ.

Expert Rev Med Devices. 2018 Feb;15(2):119-126. doi: 10.1080/17434440.2018.1421456. Epub 2018 Jan 2. Review. Erratum in: Expert Rev Med Devices. 2018 Feb;15(2):i.

PMID:
29271661
5.

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.

Carneiro BA, Kaplan JB, Giles FJ.

Expert Rev Hematol. 2015 Aug;8(4):457-79. doi: 10.1586/17474086.2015.1041910. Epub 2015 May 4. Review.

PMID:
25938861
6.

Real-world chart review study of adverse events management in patients taking tyrosine kinase inhibitors to treat metastatic renal cell carcinoma.

Srinivas S, Stein D, Teltsch DY, Tao S, Cisar L, Ramaswamy K.

J Oncol Pharm Pract. 2018 Dec;24(8):574-583. doi: 10.1177/1078155217719583. Epub 2017 Jul 21.

PMID:
28732453
7.

Effectiveness of the Medtep Hemophilia online platform for adherence to prophylactic treatment in haemophilia patients: Results from a 1-year observational study.

Cuesta-Barriuso R, López-Pina JA, Nieto-Munuera J, Sagarra-Valls G, Panisello-Royo JM, Torres-Ortuño A.

Haemophilia. 2018 May;24(3):452-459. doi: 10.1111/hae.13444. Epub 2018 Mar 1.

PMID:
29493864
8.

Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role of the midlevel practitioner.

Cornelison M, Jabbour EJ, Welch MA.

J Support Oncol. 2012 Jan-Feb;10(1):14-24. doi: 10.1016/j.suponc.2011.08.001.

PMID:
22244674
9.

The impact of a telemedicine monitoring system on positive airway pressure adherence in patients with obstructive sleep apnea: a randomized controlled trial.

Fox N, Hirsch-Allen AJ, Goodfellow E, Wenner J, Fleetham J, Ryan CF, Kwiatkowska M, Ayas NT.

Sleep. 2012 Apr 1;35(4):477-81. doi: 10.5665/sleep.1728.

10.

Augmented Reality as a Telemedicine Platform for Remote Procedural Training.

Wang S, Parsons M, Stone-McLean J, Rogers P, Boyd S, Hoover K, Meruvia-Pastor O, Gong M, Smith A.

Sensors (Basel). 2017 Oct 10;17(10). pii: E2294. doi: 10.3390/s17102294.

11.

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.

Cuellar S, Vozniak M, Rhodes J, Forcello N, Olszta D.

J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4. Review.

12.

Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.

Zuo RC, Apolo AB, DiGiovanna JJ, Parnes HL, Keen CM, Nanda S, Dahut WL, Cowen EW.

JAMA Dermatol. 2015 Feb;151(2):170-7. doi: 10.1001/jamadermatol.2014.2734.

PMID:
25427282
13.

Non-adherence to telemedicine interventions for drug users: systematic review.

Moreira Tde C, Signor L, Figueiró LR, Fernandes S, Bortolon CB, Benchaya MC, Ferigolo M, Barros HM.

Rev Saude Publica. 2014 Jun;48(3):521-31. Review. English, Portuguese.

14.

Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.

Kato R, Obara W, Matsuura T, Kato Y, Iwasaki K, Fujioka T.

Jpn J Clin Oncol. 2014 May;44(5):479-85. doi: 10.1093/jjco/hyu018. Epub 2014 Mar 30.

PMID:
24688083
15.

Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment.

Kekäle M, Peltoniemi M, Airaksinen M.

Patient Prefer Adherence. 2015 Dec 8;9:1733-40. doi: 10.2147/PPA.S92125. eCollection 2015.

16.

Adherence to diabetes self care for white, African-American and Hispanic American telemedicine participants: 5 year results from the IDEATel project.

Trief PM, Izquierdo R, Eimicke JP, Teresi JA, Goland R, Palmas W, Shea S, Weinstock RS.

Ethn Health. 2013;18(1):83-96. doi: 10.1080/13557858.2012.700915. Epub 2012 Jul 5.

PMID:
22762449
18.

Telemedicine and adherence to national guidelines for ADHD evaluation: a case study.

Nelson EL, Duncan AB, Peacock G, Bui T.

Psychol Serv. 2012 Aug;9(3):293-7. doi: 10.1037/a0026824.

PMID:
22867121
19.

Sequential plasma angiogenic factors levels in women with suspected preeclampsia.

Baltajian K, Bajracharya S, Salahuddin S, Berg AH, Geahchan C, Wenger JB, Thadhani R, Karumanchi SA, Rana S.

Am J Obstet Gynecol. 2016 Jul;215(1):89.e1-89.e10. doi: 10.1016/j.ajog.2016.01.168. Epub 2016 Jan 28.

PMID:
26827880
20.

Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.

de Almeida MH, Fogliatto L, Couto D.

Rev Bras Hematol Hemoter. 2014;36(1):54-9. doi: 10.5581/1516-8484.20140014. Review.

Supplemental Content

Support Center